We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AbbVie Ramps Up Attack on FDA’s Approach to Biosimilar Labeling
AbbVie Ramps Up Attack on FDA’s Approach to Biosimilar Labeling
AbbVie is launching new attacks on the FDA’s approach to biosimilar labeling, arguing in a letter posted to regulations.gov that the labels have “indefensible” omissions of how biosimilars and brandname biologics differ.